** Shares of Hbm Holdings 2142.HK climb 2.3% to HK$13.2, on course for the biggest one-day pct gain since Nov 14

** Hbm said the scope of collaboration with AstraZeneca AZN.L was further advanced following an amendment to an earlier agreement, aiming to develop next-generation biotherapeutics including antibody-drug conjugates and T cell engagers

** The therapeutics developer for immuno-oncology and immunology diseases said the economic terms remain consistent with the financial framework established under the agreement

** YTD, stock up 590%, Hang Seng Biotech Index .HSBIO up 77.2%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))